Kevin B Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7513033/publications.pdf Version: 2024-02-01



KEVIN R KIM

#	Article	IF	CITATIONS
1	A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma. Cancer Biotherapy and Radiopharmaceuticals, 2022, 37, 11-16.	1.0	5
2	Analysis of the effect of systemic corticosteroids on survival from tebentafusp in a phase 3 trial of metastatic uveal melanoma Journal of Clinical Oncology, 2022, 40, 9584-9584.	1.6	1
3	Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach. Journal of Investigative Dermatology, 2021, 141, 2028-2036.e2.	0.7	17
4	Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies. British Journal of Cancer, 2020, 122, 648-657.	6.4	11
5	Diffuse granulomatous panniculitis associated with anti PD-1 antibody therapy. JAAD Case Reports, 2018, 4, 13-16.	0.8	13
6	Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study. Cancer Epidemiology, 2018, 57, 80-84.	1.9	7
7	Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs. Clinical and Experimental Metastasis, 2018, 35, 503-520.	3.3	9
8	Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies. BMC Cancer, 2018, 18, 490.	2.6	73
9	Intraoperative Imaging with a Portable Gamma Camera May Reduce the False-Negative Rate for Melanoma Sentinel Lymph Node Surgery. Annals of Surgical Oncology, 2018, 25, 3326-3333.	1.5	19
10	Clinicopathological features and clinical outcomes associated with <i>TP53</i> and <i>BRAF</i> ^{<i>N</i>} ^{<i>onâ€</i>} ^{<i>V</i>} ^{<i>600</i>} mutations in cutaneous melanoma patients. Cancer, 2017, 123, 1372-1381.	4.1	36
11	A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma. Cancer Immunology, Immunotherapy, 2017, 66, 1359-1366.	4.2	29
12	A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors. BMC Cancer, 2017, 17, 173.	2.6	12
13	Overall Survival and Durable Responses in Patients With <i>BRAF</i> V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. Journal of Clinical Oncology, 2016, 34, 871-878.	1.6	266
14	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget, 2015, 6, 12809-12821.	1.8	86
15	Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. European Journal of Cancer, 2015, 51, 1435-1443.	2.8	61
16	Intratumoral talimogene laherparepvec therapy in melanoma. Melanoma Management, 2015, 2, 297-300.	0.5	2
17	Nivolumab in the treatment of advanced melanoma. Expert Opinion on Orphan Drugs, 2015, 3, 945-956.	0.8	0
18	Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. BMC Cancer, 2015, 15, 61.	2.6	25

Κενιν Β Κιμ

#	Article	IF	CITATIONS
19	Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report. BMC Cancer, 2015, 15, 400.	2.6	38
20	Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. European Journal of Cancer, 2015, 51, 2689-2697.	2.8	69
21	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. Journal of Investigative Dermatology, 2015, 135, 508-515.	0.7	138
22	Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With <i>BRAF</i> ^{V600} -Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. Journal of Clinical Oncology, 2014, 32, 3697-3704.	1.6	173
23	Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (CSK2118436). Clinical Cancer Research, 2014, 20, 4449-4458.	7.0	56
24	Treatment of KIT-mutated metastatic mucosal melanoma. Chinese Clinical Oncology, 2014, 3, 35.	1.2	18
25	Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (CSK2118436) in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2013, 31, 3205-3211.	1.6	395
26	Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAF ^{V600E} Mutation. Thyroid, 2013, 23, 1277-1283.	4.5	184
27	MEK Inhibition in the Treatment of Advanced Melanoma. Current Oncology Reports, 2013, 15, 473-482.	4.0	21
28	Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib. Melanoma Research, 2013, 23, 175-178.	1.2	46
29	Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. Journal of Clinical Oncology, 2013, 31, 482-489.	1.6	439
30	Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2013, 31, 1767-1774.	1.6	335
31	Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. Journal of Clinical Oncology, 2013, 31, 3182-3190.	1.6	530
32	A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Research, 2012, 22, 294-301.	1.2	53
33	Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. New England Journal of Medicine, 2012, 367, 1694-1703.	27.0	2,445
34	Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib. New England Journal of Medicine, 2012, 366, 707-714.	27.0	1,955
35	Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncology, The, 2012, 13, 782-789.	10.7	479
36	<i>NRAS</i> mutation status is an independent prognostic factor in metastatic melanoma. Cancer, 2012, 118, 4014-4023.	4.1	589

κένιν Β Κιμ

#	Article	IF	CITATIONS
37	Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma Journal of Clinical Oncology, 2012, 30, 8510-8510.	1.6	41
38	Prognostic factors for survival in melanoma patients with brain metastases. Cancer, 2011, 117, 1687-1696.	4.1	433
39	Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma. Clinical Cancer Research, 2011, 17, 7451-7461.	7.0	115
40	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 2010, 467, 596-599.	27.8	1,610
41	Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. New England Journal of Medicine, 2010, 363, 809-819.	27.0	3,288
42	Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. Cancer Chemotherapy and Pharmacology, 2009, 64, 161-167.	2.3	5
43	A randomized phase III trial of biochemotherapy versus interferon-α-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Research, 2009, 19, 42-49.	1.2	37
44	A phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer, 2005, 104, 1687-1692.	4.1	57
45	Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer, 2004, 100, 1478-1483.	4.1	92
46	Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Cancer, 2004, 101, 596-603.	4.1	18
47	Identification of a novel synthetic triterpenoid, methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate, that potently induces caspase-mediated apoptosis in human lung cancer cells. Molecular Cancer Therapeutics, 2002, 1, 177-84.	4.1	45